Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: Results from AMAGINE-1 - 21/04/16
Bruce Strober, MD, PhD, University of Connecticut, Farmington, CT, United States; Kenneth Gordon, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Matthias Augustin, MD, University Medical Center Hamburg, Hamburg, Germany; Hema Viswanathan, PhD, Amgen, Thousand Oaks, CA, United States; Paul Klekotka, MD, Amgen, Thousand Oaks, CA, United States; Cassandra Milmont, PhD, Amgen, Thousand Oaks, CA, United States; Gregory Kricorian, MD, Amgen, Thousand Oaks, CA, United States; David Harrison, PhD, Amgen, Thousand Oaks, CA, United States; Lionel Pinto, MS, Amgen, Thousand Oaks, CA, United States; Ajay Nirula, MD, PhD, Amgen, Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF.| Cosponsored by Amgen and AstraZeneca. |
Vol 74 - N° 5S1
P. AB256 - mai 2016 Retour au numéro
Article précédent
- Improvements in health-related quality of life measured by SF-36 and EQ-5D in patients with moderate to severe plaque psoriasis treated with brodalumab
- Insurance coverage of biologics for moderate-to-severe psoriasis: A database review
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?